Vivos Therapeutics (VVOS) Operating Expenses (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Operating Expenses for 7 consecutive years, with $7.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses rose 11.51% year-over-year to $7.8 million in Q2 2026; TTM through Jun 2026 was $35.5 million, a 59.28% increase from a year earlier, with the FY2025 full-year figure at $30.4 million, up 50.75% from the prior year.
• Operating Expenses was $7.8 million for Q2 2026 at Vivos Therapeutics, down from $9.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $9.7 million in Q1 2026 and troughed at $4.6 million in Q2 2024.
• A 5-year average of $7.2 million and a median of $7.2 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses slumped 31.84% in 2023 and surged 91.11% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at $8.4 million in 2022, then slipped by 26.34% to $6.2 million in 2023, then dropped by 21.2% to $4.9 million in 2024, then surged by 91.11% to $9.4 million in 2025, then fell by 16.99% to $7.8 million in 2026.
• The last three Operating Expenses figures came in at $7.8 million (Q2 2026), $9.7 million (Q1 2026), and $9.4 million (Q4 2025), per Business Quant data.